Leading on Biosimilars: The 2017 AAM Biosimilars Council Conference
September 12-13, 2017
Washington Marriott Wardman Park
Join us at our 2017 two-day conference - Leading on Biosimilars. Hear presentations from key industry leaders, U.S. Government agency officials, and academic experts. This interactive conference will provide you with the opportunity to learn the most up-to-date information regarding regulatory, reimbursement, legal, political, and policy environments surrounding access to biosimilar products. A key focus of this conference will be sessions dedicated to educating the public, the patients, and the healthcare professionals, about the safety and effectiveness of biosimilars. More information is available here. For registration or sponsorship details please contact Aquera Agee 202.249.7138 or Aquera.Agee@accessiblemeds.org.
The Next Drugs: The Future for Biosimilars, An Atlantic Policy Briefing
March 15, 2017
Join The Atlantic as we gather key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them? More information is available here.
The Next Drugs: An Atlantic Policy Briefing on Biosimilars
December 7, 2016
Underwritten by The Biosimilars Council
The Atlantic gathered key stakeholders to examine the emerging world of biosimilars and their regulatory framework in the United States. How does the Food and Drug Administration implement the biosimilar approval pathway? Do biosimilar drugs require the same clinical trials as the biologics on which they are modeled? How will the process impact access and affordability, and what does it mean for innovation?
The briefing featured opening remarks from the Council followed by three moderated discussions with key speakers representing the Hill, industry, regulatory experts and the patient community. Below is the complete list of featured speakers.
• Sen. Bill Cassidy (R-LA)
• Rep. Gene Greene (D-TX)
• Kimberly Greco, Director of Global Regulatory and Research and Development Policy, Amgen
• Hillel Cohen, Executive Director for Scientific Affairs, Sandoz
• David Rosen, Partner, Foley & Lardner LLP
• Robert Ratner, Chief Scientific and Medical Officer, American Diabetes Association
As we shared, this was a standing-room only event that had more than 220 registrants. While the event was livestreamed on the both the event website and GPhA website, we had approximately 120 participants attend the event in person, including key representatives from:
• Bipartisan Policy Center
• Congressional Budget Office
• Bureau of Labor Statistics
• Office of Sen. Orrin Hatch (R-UT)
• Arthritis Foundation
• American Kidney Fund
• Cancer Support Community
• Chron’s and Colitis Foundation
• March of Dimes
• National Organization for Rare Disorders
• National Patient Advocate Foundation
• Susan G. Komen
• Association of American Medical Colleges
• American Academy of Family Physicians
• National Consumers League
• Third Way
• Eli Lilly
• Johnson & Johnson
We had 8 members of the press in attendance, including reporters from Health Affairs, The RPM Report, FDA Week, and the National Journal. Below are links to some of the media coverage we’ve seen since the event.
• "Cassidy Says Obamacare Repeal Will Not Repeal Biosimilars Approval Pathway"
Regulatory Affairs Professional Society
• "Cassidy And Green: BPCIA Likely To Be Carved Out From ACA Repeal" Inside Health Policy
• "Sen. Cassidy: Biosimilars Uptake Would Increase By Making Patients Pay More For Innovator Products"
Inside Health Policy
Social and Digital:
Both the AtlanticLIVE and GPhA live-tweeted the full event via the dedicated hashtag #ATLPoliticsPolicy and additionally promoted the event and hashtag on Facebook, where they have uploaded several photos from the event. Additionally, we have posted a blog entry on GPhA’s website, highlighting key takeaways from the event, which you can find here. An early top-line look at social impact includes:
• GPhA tweeted 60 times
• Over 9,600 organic impressions
• The Atlantic had over 850k Twitter impressions reaching more than 185k Twitter accounts
• Nearly 200 unique Tweets to the #ATLPoliticsPolicy
Leading on Biosimilars: The 2016 GPhA Biosimilars Council Conference
September 7-8, 2016
Bethesda North Marriott Hotel and Conference Center,
North Bethesda, MD
Join us for the first conference hosted by the GPhA Biosimilars Council. Hear presentations from industry leaders, FDA officials, academia and others. Topics will include biosimilars education, access, the regulatory environment, reimbursement and legal affairs. More information is available here. For registration or sponsorship details please contact Aquera Agee 202.249.7138 or firstname.lastname@example.org.